Beyond Wegovy: The Next Generation of Weight Loss Drugs-Retatrutide, Oral GLP-1s, and What’s Coming by 2030

Five years after the FDA approved the first GLP-1 injection for weight loss, the obesity drug market has been transformed beyond recognition — and the transformation is still accelerating. Injections have given way to daily pills. Daily pills may soon compete with monthly shots. And a new class of drugs is now demonstrating weight loss at a level that was previously only achievable through surgery. Here is what is coming and what it means for patients.

Contents

1. How we got here — five years of GLP-1 transformation
2. The full pipeline: every major drug to know
3. Retatrutide: the most powerful weight loss drug ever tested
4. The pill revolution: oral GLP-1s reshape the market
5. New frontiers: amylin analogs, monthly shots, and beyond
6. The market opportunity: a $150 billion industry by 2035
7. What this means for patients right now

How we got here — five years of GLP-1 transformation

The approval of semaglutide (Wegovy) for weight management in 2021 marked a genuine turning point in how medicine treats obesity. For the first time, a drug delivered the kind of clinically meaningful weight reduction — around 15% of body weight on average — that had previously required surgical intervention. The market responded with extraordinary demand that outpaced manufacturing capacity for years, creating shortages that became a persistent news story in their own right.

What followed was a surge of pharmaceutical investment that shows no sign of slowing. GLP-1 receptor agonist prescriptions for adults with overweight or obesity in the United States grew by nearly 587% between 2019 and 2024. Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market capitalisation — driven almost entirely by the success of its obesity and diabetes franchise. The question facing the industry now is not whether these drugs work, but which version will work best for which patient, and what comes next when GLP-1 alone is no longer the most effective option available.

The full pipeline: every major drug to know

The landscape of obesity pharmacotherapy in 2026 spans multiple generations of drugs, delivery mechanisms, and biological targets. Here is a guide to the major candidates currently in or approaching late-stage development.

Retatrutide: the most powerful weight loss drug ever tested

The standout result from the American Diabetes Association’s Scientific Sessions in June 2026 was Eli Lilly’s presentation of full Phase 3 data for retatrutide — a drug that has now demonstrated weight loss at a level that places it in a category entirely its own. At the highest dose over 80 weeks in the TRIUMPH-1 trial, participants lost an average of 28% of their total body weight. Nearly half of all participants lost more than 30% — a threshold that had previously been associated almost exclusively with bariatric surgery.

The key Phase 3 numbers: Retatrutide at 12mg over 80 weeks produced average weight loss equivalent to 71.2 lbs. Nearly 50% of participants lost more than 30% of their body weight. All three doses (4mg, 9mg, 12mg) met both primary and key secondary endpoints. The 12mg group had an 11% discontinuation rate — similar to Zepbound — while the 4mg group posted a notably lower 4% discontinuation rate.

Retatrutide works by simultaneously activating three hormone receptors rather than the two targeted by Zepbound or the single receptor targeted by Wegovy. The addition of glucagon receptor activity to the dual GLP-1 and GIP mechanism appears to drive meaningfully greater weight loss by engaging an additional metabolic pathway. The drug is being studied across seven Phase 3 clinical trials, examining its effects not only on obesity but also on type 2 diabetes, knee osteoarthritis, sleep apnea, cardiovascular outcomes, chronic lower back pain, and liver disease.

Despite its extraordinary efficacy, retatrutide is unlikely to become the most widely prescribed obesity drug. Its greatest advantage is in the population with the most severe obesity — people with a body mass index above 40 — where other treatments may not achieve sufficiently healthy target body weights even when producing average responses. Lilly expects to file for regulatory approval in 2026, with launch projected around 2028 and peak annual sales forecast at approximately $30 billion.

The competitive response: Novo Nordisk is racing to develop its own triple-agonist candidate. In early 2025, it paid up to $2 billion for rights to an early-stage triple-agonist drug from Chinese pharmaceutical firm United Laboratories International — a direct attempt to match retatrutide’s mechanism. However, Novo’s drug remains several years behind in development, meaning retatrutide is likely to be first to market in this category by a significant margin.

The pill revolution: oral GLP-1s reshape the market

One of the most consequential developments in obesity pharmacotherapy in 2025 and 2026 has been the arrival of oral GLP-1 drugs — pills that deliver the same biological mechanism as the injections but in a form that millions of patients find significantly more acceptable. Injections carry a meaningful adherence burden: weekly self-injection is a persistent reminder of chronic disease management, and needle anxiety is a genuine barrier for a substantial share of potential patients.

Eli Lilly’s orforglipron, now branded as Foundayo, received FDA approval in early 2026 and represents a particular advance because it is a small-molecule drug rather than a peptide. Peptide-based drugs must be injected because the digestive system would break them down before they could reach the bloodstream. Small-molecule drugs survive oral digestion and can be taken like any standard tablet — simpler to manufacture, easier to distribute, and familiar to patients. Novo Nordisk has introduced its own peptide-based GLP-1 pill, but the distinction between peptide and small-molecule oral formulations matters for manufacturing economics and long-term price competition.

The race for second place: With orforglipron already approved, the next wave of oral GLP-1 developers is competing for the second-place position in the small-molecule pill market. Structure Therapeutics, which presented Phase 2 data showing approximately 16% weight loss — comparable to existing pill options — is targeting its Phase 3 trial start for later in 2026, with potential market entry in the late 2020s, assuming positive results.

New frontiers: amylin analogs, monthly shots, and beyond

The next phase of obesity drug innovation is not just about stronger versions of the same mechanism. Several companies are pursuing fundamentally different biological approaches — and one of the most watched is the amylin pathway.

Petrelintide: targeting the tolerability gap

Developed by Zealand Pharma in partnership with Roche, petrelintide works by mimicking amylin — a hormone produced in the pancreas alongside insulin that contributes to satiety signalling. It operates through a completely separate mechanism from GLP-1, meaning its side effect profile is also distinct. Phase 2 data showed approximately 11% weight loss over the trial period — lower than Wegovy or Zepbound, but with a substantially lower rate of nausea and vomiting, which are the most commonly cited reasons for discontinuing GLP-1 therapy.

Zealand’s argument is that tolerability will become an increasingly decisive competitive factor as the market matures and patients who have struggled with GLP-1 side effects — or who have stopped GLP-1 treatment because of them — seek alternatives. The company believes an “iPhone moment” is possible for obesity treatment: a point where a new product delivers a sufficiently better patient experience that users upgrade rather than staying on existing medications.

Monthly and quarterly injections: removing the weekly burden

Both Amgen and Pfizer are developing longer-acting formulations that dramatically reduce injection frequency. Amgen’s MariTide is being tested at monthly and quarterly dosing intervals. The competitive logic is straightforward — for patients who are willing to inject but find weekly dosing burdensome, a monthly or quarterly schedule lowers the constant reminder of disease management and may meaningfully improve long-term adherence.

The market opportunity: a $150 billion industry by 2035

The scale of the commercial opportunity in obesity pharmacotherapy is difficult to overstate. Morgan Stanley projects the overall cardiometabolic medicine market — which includes obesity, diabetes, cardiovascular drugs, and adjacencies — will reach $150 billion by 2035. Clarivate’s Drugs to Watch 2026 report projects retatrutide alone will generate $30 billion in annual revenue by 2031. Orforglipron is projected to reach $16 billion in that same year.

These projections reflect not just weight loss but the expanding therapeutic footprint of GLP-1 and related drugs. Semaglutide and tirzepatide have demonstrated effects on sleep apnea, cardiovascular disease, kidney disease, liver disease, and addiction — and those secondary benefits are driving additional prescribing, additional coverage decisions, and additional regulatory approvals that extend the market well beyond obesity alone.

The Novo Nordisk CEO’s framing of obesity as a fragmented, heterogeneous condition — comparable to mental health, which has diversified from a single category into dozens of distinct diagnoses with distinct treatments over the past four decades — points toward the long-term direction. The obesity drug market of 2030 is likely to be a portfolio of specialised drugs targeting different severity levels, tolerability profiles, delivery preferences, and comorbidities, rather than a single winner-take-all competition.

What this means for patients right now

For the millions of people currently using or considering obesity pharmacotherapy, the practical implications of the expanding pipeline are significant — and mostly positive, though they require some patience.

• If you are currently on Wegovy or Zepbound and achieving good results, there is no clinical reason to switch — these remain approved, well-studied treatments with strong real-world track records.
• If you prefer not to inject, FDA-approved oral options are now available for the first time, with more competition expected in the next two to three years that may bring prices down.
• If you have a BMI above 40 and have not achieved a sufficiently healthy weight on current medications, retatrutide — when approved, likely around 2028 — may offer a meaningful step forward.
• If side effects have caused you to stop treatment, the amylin pathway drugs currently in Phase 2 may offer an alternative within the next three to five years.
• If a weekly injection is a barrier, monthly dosing options from Amgen and Pfizer are expected to enter late-stage development and eventually the market by the end of the decade.

The bottom line for patients: The obesity drug market in 2029 will look radically different from today. Dozens of competing drugs are expected to be available or near market simultaneously, which means more choice, more tailored treatment, and — driven by competitive pressure — gradually improving access and affordability. The era of one-size-fits-all obesity treatment is ending.